Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
News
11/18/2026
Stephanie Holland
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the...
11/18/2026
Oncology
FDA Approval
11/10/2026
Emily Estrada
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an...
11/10/2026
Oncology
News
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology